Deactivating the F protein prevents the virus from fusing with its targets cell membrane and prevents the virus from entering the host cell. Pharmacodynamics
Palivizumab has demonstrated a significantly higher affinity and potency in neutralizing both A and B subtypes of RSV when compared with RSV-IGIV. Treatment with 2.5 mg/kg of palivizumab led to a serum concentration of 25-30 μg/mL in cotton rats and reduced RSV titers by 99% in their lungs. Pharmacokinetics
Absorption
A 2008 meta-analysis found that palivizumab absorption was quicker in the pediatric population compared to adults (ka = 1.01/day vs. ka = 0.373/day). The intramuscular bioavailability of this drug is approximately 70% in healthy young adults. Current recommendation for RSV immunoprophylaxis is administration of 5 x 15 mg/kg doses of palivizumab to maintain body concentrations above 40 μg/mL. Distribution
The volume of distribution is approximately 4.1 liters. Clearance
Palivizumab has a drug clearance (CL) of approximately 198 ml/day. The half-life of this drug is approximately 20 days with three doses sustaining body concentrations that will last the entire RSV season (5 to 6 months). A 2008 meta-analysis estimated clearance in the pediatric population by considering maturation of CL and body weight which showed a significant reduction compared to adults. Side effects
Palivizumab use may cause side effects, which include, but are not limited to:
Sore throat
Runny nose
Redness or irritation at the injection site
Vomiting
DiarrheaSome more serious side effects include:

Severe skin rash
Itching
Hives (urticaria)
Difficulty breathing

Contraindications
Contraindications for the use of palivizumab include hypersensitivity reactions upon exposure to palivizumab. Serious cases of anaphylaxis have been reported after exposure to palivizumab.
Sular may refer to:

Nisoldipine, a pharmaceutical
Sular, Iran, a village